More Business Wire
View Older Stories View Newer Stories-
Boomi Appoints Matt Heinz as Chief Revenue Officer
-
AndHealth and Jane Pauley Community Health Center Partner to Address Specialty Care Access Crisis in Indiana
-
Atropos Health Partners with Arcadia to Democratize Access to Real World Evidence for Value-Based Care Decision Making
-
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)
-
Cleveland-Cliffs to Announce Full-Year and Fourth-Quarter 2023 Earnings Results on January 29 and Host Conference Call on January 30
-
Lucky Bucks Files RICO Lawsuit Against Former Employees Alleging Systematic Looting of Company as Part of Years-long Organized Criminal Conspiracy Prior to Bankruptcy
-
F5 to Report First Quarter Fiscal Year 2024 Financial Results
-
OrbiMed Invests in Strategic Partnership With Nanotronics
-
Butterfly to Participate at the 26th Annual Needham Growth Conference
-
Omni Design Technologies Unveils Next-Gen LiDAR Solutions with Swift™ Data Converters
-
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
-
Blackstone Mortgage Trust Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
-
Forum Energy Technologies Completes Acquisition of Variperm Energy Services
-
Quectel Responds to the Request by the House Select Committee on China to Consider Barring U.S. Investments in the Company
-
Newegg Seeks to Strengthen Tech E-Commerce Leadership as 2024 Consumer Electronics Show Exhibitor
-
Hilton Grand Vacations Announces Proposed Offering of Senior Secured Notes
-
GordonMD® Announces Second Investment in Radiopharmaceutical Biotech Radionetics Oncology
-
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
-
AshBritt Foundation Supports Nancy J. Cotterman Center
-
Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH
-
OneSpan Inc. Announces Leadership Change
-
Continental and Aurora Finalize Design of World’s First Scalable Autonomous Trucking System
-
Robert Denton Elected as Chairman of the Board of Trustees
-
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
-
A10 Networks to Announce Fourth Quarter and Full Year 2023 Financial Results on February 6, 2024
-
Twist Bioscience Appoints Adam Laponis as Chief Financial Officer
-
Cardurion Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
-
Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline
-
Leavitt Equity Partners Closes $180 Million Fund III, Surpassing $150 Million Target
-
Heliogen’s CEO to Lead Public Presentation in Sidoti’s Virtual Investor Conference
-
Janus Henderson to Report Fourth Quarter and Full-Year 2023 Results
-
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
-
New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program
-
FHLBank Pittsburgh Announces 2024 Board Leadership
-
Evercore ISI to Host 10th Annual Utility CEO Conference, January 11-12, 2024
-
Digimarc to Present at 26th Annual Needham Growth Conference
-
Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024
-
Wells Fargo to Announce Fourth Quarter 2023 Earnings on Jan. 12, 2024
-
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
-
Advance Auto Parts Names Elizabeth Dreyer Chief Accounting Officer
-
Byline Bancorp, Inc. to Announce Fourth Quarter 2023 Financial Results on Thursday, January 25
-
Gannett to Present at the 26th Annual Needham Growth Conference
-
Ingersoll Rand Schedules Fourth Quarter 2023 Earnings Release and Conference Call
-
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
-
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIS
-
Marti Announces Completion of Redemption of Outstanding Warrants
-
Neurogene Announces Business Update and 2024 Outlook
-
Boxlight Corporation Board of Directors Announces Leadership Changes
-
SimBioSys® Elevates Leadership Team as It Receives First FDA Clearance for Digital Precision Medicine Platform, TumorSight™
